---
title: "National Ataxia Foundation Partners with Biogen to Bring Bill Nye \"the Science Guy\" Back To the Lab With New Series About Friedreich Ataxia"
description: "MINNEAPOLIS, Sept. 25, 2025 /PRNewswire/ -- The National Ataxia Foundation ( NAF ) today announced the launch of The Science Guy: Back in the Lab for FA, a new educational campaign to raise awareness "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258887662.md"
published_at: "2025-09-25T12:36:56.000Z"
---

# National Ataxia Foundation Partners with Biogen to Bring Bill Nye "the Science Guy" Back To the Lab With New Series About Friedreich Ataxia

> MINNEAPOLIS, Sept. 25, 2025 /PRNewswire/ -- The National Ataxia Foundation ( NAF ) today announced the launch of The Science Guy: Back in the Lab for FA, a new educational campaign to raise awareness and understanding of Friedreich ataxia ( FA ) , a rare, genetic disease.

MINNEAPOLIS, Sept. 25, 2025 /PRNewswire/ -- The National Ataxia Foundation ( NAF ) today announced the launch of The Science Guy: Back in the Lab for FA, a new educational campaign to raise awareness and understanding of Friedreich ataxia ( FA ) , a rare, genetic disease.

### Related Stocks

- [BIIB.US - Biogen](https://longbridge.com/en/quote/BIIB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 中國給予 Biogen 和 Eisai 的皮下注射 LEQEMBI 申請優先審查 | Biogen Inc. 和 Eisai Co., Ltd. 已獲得中國國家藥品監督管理局對其 LEQEMBI®（lecanemab）皮下給藥製劑生物製品許可申請的優先審評資格。該資格旨在加快藥物的評估和潛在上市，這將提供一種每週一次的居家給 | [Link](https://longbridge.com/en/news/275253143.md) |
| Biogen：有限的短期增長和執行風險使得中性持有評級是合理的 | 摩根士丹利分析師 Terence Flynn 維持了對 Biogen 的持有評級，目標價為 190.00 美元，理由是短期增長有限和執行風險。管理層的 2026 年指引顯示收入將小幅下降，核心產品銷售預計將收縮。儘管新產品發佈和關鍵事件可能 | [Link](https://longbridge.com/en/news/275233131.md) |
| Biogen｜10-K：2025 財年營收 98.91 億美元超過預期 |  | [Link](https://longbridge.com/en/news/275127544.md) |
| 關鍵事實：Biogen 的 LEQEMBI 在中國獲得優先審查；Wedbush 上調了其目標價格 | Biogen 和 Eisai 的 LEQEMBI（lecanemab）皮下給藥製劑獲得了中國國家藥品監督管理局的優先審評，加快了其審批進程。Wedbush 將 Biogen（BIIB）股票的目標價從 178.00 美元上調至 187.00  | [Link](https://longbridge.com/en/news/275506245.md) |
| Biogened SA - 第四季度財務報告 | 附加附件請見下方：20260216_124521_0000001185_0000063957.pdf   newsfile.refinitiv.com/getnewsfile/v1/story20260216_124521_00000011 | [Link](https://longbridge.com/en/news/276054417.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.